Melanoma Trial, Recruiting (NCT04605146)

Melanoma Trial, Recruiting NCT04605146 Sponsor: Hospices Civils de Lyon Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT04605146 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are over 18 years old
People who have been diagnosed with melanoma, lung cancer, or kidney cancer
People who are starting a treatment combining two immunotherapy drugs called nivolumab and ipilimumab (people who have had immunotherapy treatment in the past may also be included)
People who are comfortable using digital devices and technology such as computers or smartphones
People who are willing to take part in remote health monitoring and have signed a consent form

Who may not be able to join:

Women who are pregnant, in labour, or breastfeeding
People who are under a legal protection order or who are not free to make their own decisions (confirm with trial site)
People who are not covered by a qualifying social security or health insurance scheme — for example, those covered only under certain limited schemes, or people from outside the European Union who do not have an equivalent arrangement (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stéphane DALLE, Department of Dermatology, HCL-Cancer Institute

Phone: 0478861679

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04605146

Sponsor: Hospices Civils de Lyon

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: 0478861679

More information: https://clinicaltrials.gov/study/NCT04605146

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are over 18 years old
People who have been diagnosed with melanoma, lung cancer, or kidney cancer
People who are starting a treatment combining two immunotherapy drugs called nivolumab and ipilimumab (people who have had immunotherapy treatment in the past may also be included)
People who are comfortable using digital devices and technology such as computers or smartphones
People who are willing to take part in remote health monitoring and have signed a consent form

Who may not be able to join:

Women who are pregnant, in labour, or breastfeeding
People who are under a legal protection order or who are not free to make their own decisions (confirm with trial site)
People who are not covered by a qualifying social security or health insurance scheme — for example, those covered only under certain limited schemes, or people from outside the European Union who do not have an equivalent arrangement (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Hospices Civils de Lyon

Registry

ClinicalTrials.gov

Start date

5 May 2021

Est. completion

5 November 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Delay between the start of a side effect and reporting to the medical team (average number of days per patient).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov